Inhaled Braylin for Asthma and COPD via Localized Lung Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for asthma and COPD often come with adverse effects such as weight gain, heart problems, and systemic toxicity, limiting their effectiveness and patient quality of life.
Innovation Solution
The use of coumarin-derived compounds, specifically braylin, formulated for inhalation to target airway diseases by reducing inflammatory cells, cytokine levels, and mucus production in the lungs.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional drug-based therapies are used to treat asthma and COPD, then therapeutic effectiveness is improved, but adverse effects such as weight gain, heart problems, and systemic toxicity increase
Solution Approach 1:
The invention segments the therapeutic action by using inhaled corticosteroids that act locally in the lungs rather than systemically. The drug is delivered directly to the target organ (lungs) through inhalation, separating the site of action from systemic circulation and thereby reducing adverse effects while maintaining therapeutic effectiveness.
Solution Approach 2:
The invention applies local quality by concentrating the corticosteroid action specifically in the lung tissue through inhalation delivery. The drug exhibits high concentration at the site of disease (airways and lung parenchyma) while minimizing systemic exposure, thus providing localized therapeutic effect with reduced harmful side effects.
2Object-affected harmful factors
If inhaled corticosteroids are used to reduce systemic absorption, then adverse effects are reduced, but complete avoidance of systemic absorption is not achieved
Solution Approach 1:
The invention accepts partial systemic absorption as unavoidable but minimizes it to a clinically acceptable level. By using inhaled corticosteroids, the system achieves sufficient local effect in the lungs while allowing only minimal systemic absorption, which is less than what would occur with oral or parenteral administration of equivalent doses.
3Reliability
If high doses of corticosteroids are administered to control severe asthma and COPD, then symptom control is improved, but the risk of systemic side effects increases proportionally
Solution Approach 1:
The invention segments the dose delivery by administering corticosteroids directly to the lungs through inhalation. This allows high local doses to be achieved in the target organ without proportionally increasing systemic exposure, thereby maintaining symptom control in severe cases while minimizing the risk of systemic side effects that would occur with equivalent systemic dosing.
Solution Approach 2:
The invention applies local quality by concentrating the high-dose corticosteroid effect specifically in the lung tissue through inhalation. The drug achieves high local concentration necessary for controlling severe asthma and COPD symptoms while the systemic circulation receives minimal exposure, decoupling the relationship between dose intensity and systemic side effect risk.
Data Source
AI summary
The present invention is part of the field of pharmacology and medicine and relates to the use of coumarin derivative compounds for the treatment of asthma and/or chronic obstructive pulmonary disease (COPD). The present inventors identified that inhaled braylin has high therapeutic efficacy in the treatment of asthma and COPD, with efficacy comparable to systemic dexamethasone, and presenting itself as an unprecedented alternative to conventional treatments.